SLC22A8 and hyperuricemia: As shown in Figure 2, benzbromarone (an anti-hyperuricemia agent, IC50 = 0.14 μM) was the most potent inhibitor against OAT3-mediated uptake of enalaprilat, while diclofenac (an anti-inflammation agent, IC50 = 6.13 μM) was the weakest inhibitor among the tested drugs.